Bladder cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• MYC 0
• ERK 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

24 of 2,077 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Artificial Intelligence Enhanced Detection and Monitoring of Bladder Cancer

  Vesica Corporation· San Marcos, United States· US$1,200,764 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort

  Veterans Education/Res/Assn/North/Ne· White River Junction, United States· US$594,869 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Population modeling for bladder cancer prevention and control

  Brown University· Providence, United States· US$1,231,387 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · P50

  SPORE in Bladder Cancer

  Sloan-Kettering Inst Can Research· New York, United States· US$2,491,899 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · F31

  Investigating the effect of high methionine availability on cancer progression

  University of Southern California· Los Angeles, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €2,000,000· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €197,264· until Mar 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Ireland· EU contribution €328,495· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Ireland· EU contribution €13,615,935· until Dec 2029· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Israel· EU contribution €2,498,731· until Nov 2026

10 of 192 running projects, newest first. Listed amounts together: US$123.2m + €36.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

  NCT02625961· Merck Sharp & Dohme LLC· Updated 13 Nov 2026

  “Business Reasons”Registry text, quoted unchanged. Source

• Withdrawn

  Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

  NCT07185945· Guru Sonpavde· Updated 9 Nov 2026

  “Funder withdrew”Registry text, quoted unchanged. Source

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Terminated

  Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

  NCT06571708· Columbia University· Updated 3 Nov 2026

  “Change in standard of care treatment for muscle-invasive bladder cancer”Registry text, quoted unchanged. Source

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Terminated

  A Study of E7130 in Participants With Solid Tumors

  NCT03444701· Eisai Co., Ltd.· Updated 23 Oct 2026

  “The trial was prematurely terminated due to the sponsor's decision.”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of Naloxegol in the Prevention of POI After Cystectomy

  NCT04219046· Institut Paoli-Calmettes· Updated 14 Oct 2026

  “the industrial partner withdrew from the study”Registry text, quoted unchanged. Source

• Terminated

  TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors

  NCT06373419· Thunder Bay Regional Health Research Institute· Updated 1 Oct 2026

  “Lack of enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

  NCT06290687· Case Comprehensive Cancer Center· Updated 24 Sept 2026

  “PI left institution”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Sasanlimab Treatment As Bladder-Sparing Strategy For Patients With Muscle Invasive Bladder Cancer

  2024-511358-36-00· Fundacion De investigacion De Hm Hospitales· Source

• Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

  NCT02625961· Merck Sharp & Dohme LLC· Source

• A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

  NCT07222488· Merck Sharp & Dohme LLC· Source

• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

  NCT03775265· National Cancer Institute (NCI)· Source

• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

  NCT07475806· Astellas Pharma Global Development, Inc.· Source

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Source

• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

  NCT03854474· National Cancer Institute (NCI)· Source

• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

  NCT04164082· National Cancer Institute (NCI)· Source

• Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

  NCT06228066· National Cancer Institute (NCI)· Source

• Evaluation for NCI Surgery Branch Clinical Research Protocols

  NCT00001823· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 79
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 78
• Genome-Wide Association Study 18

• Characterization of a 64Cu-Labeled Heterobivalent Bicyclic Peptide (Nectin-4/Albumin) for Targeting of Tumor-Associated Nectin-4.

  Mol Pharm, Nov 2026

• Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer.

  Mol Pharm, Nov 2026

• Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma.

  J Med Chem, Oct 2026

• "Imaging Triplets on Two Wheels": 61Cu-, 64Cu-, and 68Ga-labeled Bicyclic Peptides Targeting Nectin-4 Enable High-Contrast PET Imaging of Urothelial Carcinoma and Triple-Negative Breast Cancer.

  Bioconjug Chem, Sept 2026

• Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

  Q J Nucl Med Mol Imaging, Jun 2026

• Design and preclinical evaluation of lipophilicity-enhanced bicyclic peptide probes targeting Nectin4 Labeled with 68Ga/18F.

  Bioorg Chem, Mar 2026

• Advances and challenges of PET imaging in bladder cancer-An update and future trends.

  Semin Nucl Med, Mar 2026

• Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma.

  Sci Adv, Jan 2026

• The role of non-FDG agents in PET imaging of bladder cancer.

  Semin Nucl Med, Dec 2025

• Is There a Role of FAPI Pet in Renal and Bladder Cancer?

  Semin Nucl Med, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.